A Phase 3 interventional study of INC424 in Myelofibrosis, sponsored by Novartis Pharmaceuticals. Completed at 273 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one has the largest enrollment, is one of 6 that started in 2011, is one of 6 in phase 3, and was the 11th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,233 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
24 studies in Primary Myelofibrosis by Novartis: 1 open now, 4 under way, 2 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 7th registered.
Novartis’s Primary Myelofibrosis studies by the year they started, since 2001.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Novartis’s 24 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior treatment with commercially available agents or who have never received treatment.
Main Inclusion Criteria:
Patients with PMF requiring therapy must be classified as high risk (3 prognostic factors) OR intermediate risk level 2 (2 prognostic factors, no more), OR intermediate risk level 1 (1 prognostic factor, no more) with an enlarged spleen (assessment to occur at the Screening Visit).
The prognostic factors, defined by the International Working Group are:
Main Exclusion Criteria:
Patients with inadequate bone marrow reserve at the Baseline visit as demonstrated by:
In the case of ruxolitinib pretreated patients, ruxolitinib primary resistant patients defined as:
AND
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 - 25 mg twice a day (BID)
Drug: INC424
All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Also known as: Ruxolitinib
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.
Time frame: Baseline up to approximately 5 years
Percentage of Participants With at Least 50% Reduction in Spleen Length
Spleen length was assessed by manual palpation. Assessment of spleen response was repeated until early discontinuation of the study drug and also at study completion (28 days post end of treatment visit).
Time frame: Baseline up to approximately 5 years
Number of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length
Overall response is analyzed using the spleen response, as assessed by the investigator and also by deriving the response using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. Participants with spleen length at baseline between 5 and 10 cm were reported as Responders if reporting non palpable spleen; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 100% from baseline in spleen length. Participants with spleen length at baseline more than 10 cm were reported as Responders with spleen reduction of 50% from baseline; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 50% from baseline in spleen length.
Time frame: Baseline up to approximately 5 years
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years
ECOG Performance Score has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. 5 = Death.
Time frame: Baseline up to approximately 5 years
Change in Functional Assessment of Cancer Therapy (FACT-TOI, FACT-G) and FACT-Lymphoma (FACT-Lym) Total Scores Measured at Baseline and Week 48
The FACT-Lym questionnaire consists of a total of 42 questions divided between five subscales (i.e., physical well-being, social/family well-being, emotional well-being, functional well-being and lymphoma subscale). Each subscale questionnaire rates each question on a 5-point scale from 0 = Not at all to 4 = Very much. These scores were summed to three total sum scores, namely FACT-Lym score, FACT-Lym Trial Outcome Index (TOI), FACT-General (FACT-G) and FACT-Lym total score. Total scores: FACT-Lym=0-60, FACT-TOI=0-116, FACT-G total=0-108, FACT-Lym Total= 0-168. Higher scores are reflective of better HRQoL.
Time frame: Baseline and Week 48
Time to First Improvement in FACT-Lym, FACIT-Fatigue Score and ECOG Performance Status
Improvement was defined by the upper limit of the minimally important difference (MID). Patients with the best possible score at Baseline were excluded from this analysis because their HRQoL cannot be further improved. Responders and non-responders for each endpoint were defined based on change from baseline scores using pre specified cut-off points. Patients with an improved score compared to Baseline, for which the magnitude of the change was at least the cutoff value, were classified as responders; otherwise, as non-responders. The responder cutoff: ECOG cutoff=1, range=0 to 5, FACT-Lym cutoff=5.4, range 0-60, FACIT-Fatigue =5 and range=0-52.The median time to first improvement was estimated using the Kaplan Meier method and time to improvement event was determined based on upper bound of the MID. The time to improvement was calculated from the date of first study drug administration.
Time frame: Baseline up to approximately 5 years
Medical Resource Utilization up to 5 Years
Percentage of patients requiring medical resources (blood transfusions, hospitalization, emergency room visits, general practitioners or specialists consultations, urgent care or splenic irradiation) up to 5 years.
Time frame: Baseline up to approximately 5 years.
This was an expanded access study intended to provide an access path to ruxolitinib for patients with Myelofibrosis (MF) and to allow for collection of additional safety and efficacy data for ruxolitinib.
| Milestone | INC424 |
|---|---|
| Started | 2233 |
| Completed | 1283 |
| Not completed | 950 |
| Withdrew: Adverse event | 405 |
| Withdrew: Disease progression | 204 |
| Withdrew: Death | 101 |
| Withdrew: Physician decision | 93 |
| Withdrew: Withdrawal by subject | 79 |
| Withdrew: Protocol deviation | 27 |
| Withdrew: Administrative problems | 25 |
| Withdrew: Lost to follow-up | 16 |
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.
| Participants | INC424 |
|---|---|
| Adverse Events | 2153 |
| Serious adverse events | 830 |
Spleen length was assessed by manual palpation. Assessment of spleen response was repeated until early discontinuation of the study drug and also at study completion (28 days post end of treatment visit).
| percentage of participants | INC424 |
|---|---|
| Percentage of Participants With at Least 50% Reduction in Spleen Length | 71.7 (69.7 to 73.7) |
Overall response is analyzed using the spleen response, as assessed by the investigator and also by deriving the response using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. Participants with spleen length at baseline between 5 and 10 cm were reported as Responders if reporting non palpable spleen; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 100% from baseline in spleen length. Participants with spleen length at baseline more than 10 cm were reported as Responders with spleen reduction of 50% from baseline; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 50% from baseline in spleen length.
| Participants | INC424 - Responders | INC424 - Stable Disease | INC424 - Progressive Disease | INC424 - Missing |
|---|---|---|---|---|
| Spleen length at baseline-Less than 5 cm | NA | NA | NA | NA |
| Spleen length at baseline-Between 5 and 10 cm | 421 | 334 | 1 | 9 |
| Spleen length at baseline-More than 10 cm | 742 | 463 | 0 | 19 |
ECOG Performance Score has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. 5 = Death.
| Participants | INC424 |
|---|---|
| Baseline - Grade 0 — Worst value post-baseline: Grade 0 | 598 |
| Baseline - Grade 0 — Worst value post-baseline: Grade 1 | 377 |
| Baseline - Grade 0 — Worst value post-baseline: Grade 2 | 62 |
| Baseline - Grade 0 — Worst value post-baseline: Grade 3 | 12 |
| Baseline - Grade 0 — Worst value post-baseline: Grade 4 | 7 |
| Baseline - Grade 0 — Worst value post-baseline: Grade 5 | 0 |
| Baseline - Grade 0 — Worst value post-baseline: Missing | 5 |
| Baseline - Grade 1 — Worst value post-baseline: Grade 0 | 89 |
| Baseline - Grade 1 — Worst value post-baseline: Grade 1 | 629 |
| Baseline - Grade 1 — Worst value post-baseline: Grade 2 | 187 |
| Baseline - Grade 1 — Worst value post-baseline: Grade 3 | 26 |
| Baseline - Grade 1 — Worst value post-baseline: Grade 4 | 12 |
| Baseline - Grade 1 — Worst value post-baseline: Grade 5 | 1 |
| Baseline - Grade 1 — Worst value post-baseline: Missing | 16 |
| Baseline - Grade 2 — Worst value post-baseline: Grade 0 | 3 |
| Baseline - Grade 2 — Worst value post-baseline: Grade 1 | 43 |
| Baseline - Grade 2 — Worst value post-baseline: Grade 2 | 111 |
| Baseline - Grade 2 — Worst value post-baseline: Grade 3 | 20 |
| Baseline - Grade 2 — Worst value post-baseline: Grade 4 | 12 |
| Baseline - Grade 2 — Worst value post-baseline: Grade 5 | 1 |
| Baseline - Grade 2 — Worst value post-baseline: Missing | 7 |
| Baseline - Grade 3 — Worst value post-baseline: Grade 0 | 0 |
| Baseline - Grade 3 — Worst value post-baseline: Grade 1 | 0 |
| Baseline - Grade 3 — Worst value post-baseline: Grade 2 | 0 |
| Baseline - Grade 3 — Worst value post-baseline: Grade 3 | 1 |
| Baseline - Grade 3 — Worst value post-baseline: Grade 4 | 0 |
| Baseline - Grade 3 — Worst value post-baseline: Grade 5 | 0 |
| Baseline - Grade 3 — Worst value post-baseline: Missing | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Grade 0 | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Grade 1 | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Grade 2 | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Grade 3 | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Grade 4 | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Grade 5 | 0 |
| Baseline - Grade 4 — Worst value post-baseline: Missing | 0 |
| Baseline - Missing — Worst value post-baseline: Grade 0 | 1 |
| Baseline - Missing — Worst value post-baseline: Grade 1 | 8 |
| Baseline - Missing — Worst value post-baseline: Grade 2 | 4 |
| Baseline - Missing — Worst value post-baseline: Grade 3 | 1 |
| Baseline - Missing — Worst value post-baseline: Grade 4 | 0 |
| Baseline - Missing — Worst value post-baseline: Grade 5 | 0 |
| Baseline - Missing — Worst value post-baseline: Missing | 0 |
The FACT-Lym questionnaire consists of a total of 42 questions divided between five subscales (i.e., physical well-being, social/family well-being, emotional well-being, functional well-being and lymphoma subscale). Each subscale questionnaire rates each question on a 5-point scale from 0 = Not at all to 4 = Very much. These scores were summed to three total sum scores, namely FACT-Lym score, FACT-Lym Trial Outcome Index (TOI), FACT-General (FACT-G) and FACT-Lym total score. Total scores: FACT-Lym=0-60, FACT-TOI=0-116, FACT-G total=0-108, FACT-Lym Total= 0-168. Higher scores are reflective of better HRQoL.
| scores on a scale | INC424 |
|---|---|
| FACT-Lymphoma Baseline | 42.3 ± 10.20 |
| FACT-Lymphoma Week 48 | 47.9 ± 8.47 |
| FACT-Lymphoma TOI Baseline | 77.9 ± 18.99 |
| FACT-Lymphoma TOI Week 48 | 86.8 ± 16.42 |
| FACT-Lymphoma total score Baseline | 113.9 ± 24.01 |
| FACT-Lymphoma total score Week 48 | 123.3 ± 22.34 |
| FACT-G Baseline | 71.6 ± 15.98 |
| FACT-G Week 48 | 75.5 ± 15.59 |
Improvement was defined by the upper limit of the minimally important difference (MID). Patients with the best possible score at Baseline were excluded from this analysis because their HRQoL cannot be further improved. Responders and non-responders for each endpoint were defined based on change from baseline scores using pre specified cut-off points. Patients with an improved score compared to Baseline, for which the magnitude of the change was at least the cutoff value, were classified as responders; otherwise, as non-responders. The responder cutoff: ECOG cutoff=1, range=0 to 5, FACT-Lym cutoff=5.4, range 0-60, FACIT-Fatigue =5 and range=0-52.The median time to first improvement was estimated using the Kaplan Meier method and time to improvement event was determined based on upper bound of the MID. The time to improvement was calculated from the date of first study drug administration.
| weeks | INC424 |
|---|---|
| FACT-Lym Total score median time to improvement | 10.9 (5.1 to 11.6) |
| FACIT - Fatigue score median time to improvement | 4.6 (4.4 to 4.6) |
| ECOG score median time to improvement | 63.1 (61.1 to 65.0) |
Percentage of patients requiring medical resources (blood transfusions, hospitalization, emergency room visits, general practitioners or specialists consultations, urgent care or splenic irradiation) up to 5 years.
| Participants | INC424 |
|---|---|
| Baseline- Dependency — End of Study - Dependency | 129 |
| Baseline- Dependency — End of Study - Independency | 29 |
| Baseline- Independency — End of Study - Dependency | 480 |
| Baseline- Independency — End of Study - Independency | 1595 |
Collected over Adverse Events (AEs) were collected up to 24-months after last patient first visit (LPFV), approximately 5 years .. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INC424 | 205/2,233 (9.2%) | 830/2,233 (37.2%) | 2,008/2,233 (89.9%) |
| Event | INC424 |
|---|---|
| PneumoniaInfections and infestations | 123/2233 |
| AnaemiaBlood and lymphatic system disorders | 94/2233 |
| PyrexiaGeneral disorders | 79/2233 |
| Cardiac failureCardiac disorders | 43/2233 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 36/2233 |
| SepsisInfections and infestations | 31/2233 |
| Abdominal painGastrointestinal disorders | 28/2233 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 26/2233 |
| ThrombocytopeniaBlood and lymphatic system disorders | 24/2233 |
| Urinary tract infectionInfections and infestations | 23/2233 |
| Event | INC424 |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1300/2233 |
| ThrombocytopeniaBlood and lymphatic system disorders | 990/2233 |
| AstheniaGeneral disorders | 331/2233 |
| PyrexiaGeneral disorders | 310/2233 |
| DiarrhoeaGastrointestinal disorders | 267/2233 |
| FatigueGeneral disorders | 215/2233 |
| Platelet count decreasedInvestigations | 198/2233 |
| HeadacheNervous system disorders | 191/2233 |
| CoughRespiratory, thoracic and mediastinal disorders | 186/2233 |
| Oedema peripheralGeneral disorders | 182/2233 |
| Age, Continuous(years) | INC424 |
|---|---|
| Mean | 65.6 ± 10.50 |
| Sex: Female, Male(Participants) | INC424 |
|---|---|
| Female | 1016 |
| Male | 1217 |
| Race (NIH/OMB)(Participants) | INC424 |
|---|---|
| American Indian or Alaska Native | 6 |
| Asian | 23 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 20 |
| White | 2087 |
| More than one race | 96 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | INC424 |
|---|---|
| Hispanic/Latino | 509 |
| Chinese | 1 |
| Indian (Indian subcontinent) | 1 |
| Japanese | 0 |
| Mixed Ethnicity | 15 |
| Others | 1707 |
| ECOG score(Participants) | INC424 |
|---|---|
| 0 | 1061 |
| 1 | 960 |
| 2 | 197 |
| 3 | 1 |
| 4 | 0 |
| Missing | 14 |
Showing the first 100 of 273 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Aug 2011, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib